Safety Perspectives on Presently Considered Drugs for the Treatment of COVID-19

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2020 Jul 19

PMID 32681537

Citations 9

Authors

Sophie L Penman

Robyn T Kiy

Rebecca L Jensen

Christopher Beoku-Betts

Ana Alfirevic

David Back

Saye H Khoo

Andrew Owen

Munir Pirmohamed

B Kevin Park

Xiaoli Meng

Christopher E Goldring

Amy E Chadwick

Affiliations

Soon will be listed here.

Abstract

Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID-19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary pharmacological strategy. Despite the urgent clinical need for these therapies, it is imperative to consider potential safety issues. This is important due to the harm-benefit ratios that may be encountered when treating COVID-19, which can depend on the stage of the disease, when therapy is administered and underlying clinical factors in individual patients. Treatments are currently being trialled for a range of scenarios from prophylaxis (where benefit must greatly exceed risk) to severe life-threatening disease (where a degree of potential risk may be tolerated if it is exceeded by the potential benefit). In this perspective, we have reviewed some of the most widely researched repurposed agents in order to identify potential safety considerations using existing information in the context of COVID-19.

Citing Articles

Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.

Attiq A, Afzal S, Wahab H, Ahmad W, Kandeel M, Almofti Y Drug Des Devel Ther. 2024; 18:4215-4240.

PMID: 39319193 PMC: 11421457. DOI: 10.2147/DDDT.S475005.

Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.

Kiy R, Khoo S, Chadwick A Toxicol Res (Camb). 2024; 13(1):tfae012.

PMID: 38328743 PMC: 10848230. DOI: 10.1093/toxres/tfae012.

Repurposing of Chemotherapeutics to Combat COVID-19.

Nandi S, Nayak B, Khede M, Saxena A Curr Top Med Chem. 2022; 22(32):2660-2694.

PMID: 36453483 DOI: 10.2174/1568026623666221130142517.

Anti-malarial drugs: Mechanisms underlying their proarrhythmic effects.

Saadeh K, Nantha Kumar N, Fazmin I, Edling C, Jeevaratnam K Br J Pharmacol. 2022; 179(24):5237-5258.

PMID: 36165125 PMC: 9828855. DOI: 10.1111/bph.15959.

Editorial: Medication Safety in COVID-19 Management.

Das S Front Pharmacol. 2022; 13:940307.

PMID: 35880232 PMC: 9307660. DOI: 10.3389/fphar.2022.940307.

References

Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F . Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015; 19(8):1965-74. PMC: 4549047. DOI: 10.1111/jcmm.12573. View

Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Singh Malik Y . Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Front Immunol. 2018; 9:597. PMC: 5925603. DOI: 10.3389/fimmu.2018.00597. View

Drepper M, Rubbia-Brandt L, Spahr L . Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease. Case Reports Hepatol. 2014; 2013:964828. PMC: 4208420. DOI: 10.1155/2013/964828. View

Chandwani A, Shuter J . Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag. 2009; 4(5):1023-33. PMC: 2621403. DOI: 10.2147/tcrm.s3285. View

Anger F, Wiegering A, Wagner J, Lock J, Baur J, Haug L . Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report. Rheumatology (Oxford). 2017; 56(9):1628-1629. DOI: 10.1093/rheumatology/kex221. View

Mallick P, Taneja G, Moorthy B, Ghose R . Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions. Expert Opin Drug Metab Toxicol. 2017; 13(6):605-616. PMC: 5714652. DOI: 10.1080/17425255.2017.1292251. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Yang B, Baughman S, Sullivan J . Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin Pharmacol Ther. 2003; 74(1):85-94. DOI: 10.1016/S0009-9236(03)00094-8. View

Keystone E, Taylor P, Drescher E, Schlichting D, Beattie S, Berclaz P . Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2014; 74(2):333-40. PMC: 4316868. DOI: 10.1136/annrheumdis-2014-206478. View

10.

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers Y . Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018; 41(10):919-931. DOI: 10.1007/s40264-018-0689-4. View

11.

Channappanavar R, Fehr A, Zheng J, Wohlford-Lenane C, Abrahante J, Mack M . IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019; 129(9):3625-3639. PMC: 6715373. DOI: 10.1172/JCI126363. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E . COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost. 2020; 120(6):998-1000. PMC: 7295272. DOI: 10.1055/s-0040-1710018. View

14.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

15.

Adalja A, Inglesby T . Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool. Expert Rev Anti Infect Ther. 2019; 17(7):467-470. PMC: 7103698. DOI: 10.1080/14787210.2019.1635009. View

16.

Ponce-Balbuena D, Rodriguez-Menchaca A, Lopez-Izquierdo A, Ferrer T, Kurata H, Nichols C . Molecular mechanisms of chloroquine inhibition of heterologously expressed Kir6.2/SUR2A channels. Mol Pharmacol. 2012; 82(5):803-13. PMC: 3477226. DOI: 10.1124/mol.112.079152. View

17.

Carter S, Tattersall R, Ramanan A . Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2018; 58(1):5-17. DOI: 10.1093/rheumatology/key006. View

18.

Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E . Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617):987-97. DOI: 10.1016/S0140-6736(08)60453-5. View

19.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

20.

Zhang L, Zhang Y, Huang S . Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm. 2009; 6(6):1766-74. DOI: 10.1021/mp900132e. View